Download as PDF
Article based on PreveCeutical’s Pain Management Peptides Program published in the British Journal of Pharmacology
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce that the British Journal of Pharmacology (the “BJP”), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program (“Analgesic Program”) under the running title, “Short dynorphin-like peptide agonists for kappa opioid receptors” click here to see the report.The article has undergone full independent peer review.
The Analgesic Program, which commenced in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation, and was successfully completed in March 2021.
The BJP is the leading international general pharmacology journal published by the British Pharmacological Society. It publishes high-quality original research and authoritative reviews, addresses topical pharmacology issues, and is committed to transparency and scientific rigour.
The class of compounds, peripheral Kappa opioid receptor (KOPr) agonists, are considered potential analgesics without the dose-limiting central nervous system-mediated side effects. The potency and duration of action of peptides identified in the study were comparable to the clinical standard morphine, in-vivo.
PreveCeutical’s Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, “Having an independent peer reviewed article from PreveCeutical’s program and having it published in the prestigious BJP is a big milestone for our non-addictive analgesic program. We will continue to assess potential partnerships to develop safer analgesics with our patent-pending peptides. Therapies based on these potentially non-addictive peptides will be important in addressing the current opioid crisis.”
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
The Company is currently in the research and development stage for dual gene curative and preventive therapies for diabetes and obesity.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, matters related to the Company’s current and planned research and development programs, including the Analgesic Program, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes”, or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, including the Company’s research and development activities, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the Analgesic Program, complexities and delays in connection with research and development activities and the actual results of research and development activities, and the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and product development programs as planned, including the Analgesic Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare and cannabis industries in Canada may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions, or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.